NCI-2025-04391

A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy andSafety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants withResected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02

The SUNRAY-02 study is a Phase 3, multicenter, double-blind, placebo-controlled research study designed to evaluate the effectiveness and safety of a new targeted therapy called Olomorasib when used in combination with standard immunotherapy in people with non-small cell lung cancer (NSCLC) that carries a KRAS G12C mutation. This mutation is one of the most common genetic changes seen in NSCLC and is known to drive cancer growth. The trial includes participants with resected (surgically removed) or unresectable (cannot be removed by surgery) KRAS G12C-mutant NSCLC. By targeting the KRAS G12C mutation, Olomorasib aims to block a key cancer growth pathway and potentially enhance the effects of immunotherapy, offering a new treatment option for patients whose cancers are difficult to treat with existing therapies.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

double blind: Neither the patients nor the doctors know who is getting what treatment. This helps make sure the results are completely not biased

Placebo: A placebo is a substance or treatment that has no active medical properties but is given to a patient as if it were a real medication or treatment. It is often used in medical research to compare the effects of a new drug or treatment with the effects of no treatment at all. The idea is to see if the new drug or treatment is genuinely effective by comparing how patients who receive the real treatment fare compared to those who receive the placebo

immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

non-small cell lung cancer (NSCLC): A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06890598

Clinical Trial Site: Columbia

To see all available clinical trials click here.